address1,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,hasPrePostMarketData,firstTradeDateMilliseconds,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,regularMarketChangePercent,regularMarketPrice,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,earningsCallTimestampStart,earningsCallTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,cryptoTradeable,sourceInterval,exchangeDataDelayedBy,marketState,corporateActions,regularMarketTime,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,shortName,longName,trailingPegRatio
Scheeles väg 5,Solna,171 65,Sweden,46 8 55 90 56 00,https://www.xbrane.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden.",64,"[{'maxAge': 1, 'name': 'Mr. Martin  Amark', 'age': 44, 'title': 'Chief Executive Officer', 'yearBorn': 1980, 'fiscalYear': 2024, 'totalPay': 3366000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Siavash  Bashiri', 'age': 41, 'title': 'COO, Head of Biosimilars & Deputy CEO', 'yearBorn': 1983, 'fiscalYear': 2024, 'totalPay': 1756000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Associate Prof. Jan-Willem  De Gier', 'title': 'Co-Founder', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Samuel  Wagner Ph.D.', 'title': 'Co-Founder & Member of Scientific Advisory Board', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jane  Benyamin', 'age': 45, 'title': 'Interim CFO & Head of IR', 'yearBorn': 1979, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Dina  Jurman', 'age': 42, 'title': 'Head of Clinical Affairs', 'yearBorn': 1982, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anders  Wallstrom', 'age': 48, 'title': 'Head of Manufacturing & Supply Chain', 'yearBorn': 1976, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Håkan  Yildirim', 'title': 'Head of Intellectual Property', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",1735603200,[],86400,4,0.2452,0.2464,0.2422,0.2542,0.2452,0.2464,0.2422,0.2542,0.0,0.737,4.876,12.190001,2872329,2872329,15245625,7164093,7164093,0.2424,0.245,0,0,373547904,0.1262,0.306,1.3442149,0.233488,0.1950545,0.0,0.0,SEK,False,517133728,-0.5781,1198341352,1532189952,0.25620002,0.10069,1557190016,0.141,1.7290779,1735603200,1767139200,1743379200,-160796992,0.05,0.02,1.861,-5.542,-0.058733225,0.1185931,EQUITY,0.2438,0.9,0.4,0.65,0.65,none,2,24709000,0.016,-93306000,149602000,0.11,1.218,277892992,69.176,0.181,-0.080240004,-0.52687,224124000,-108296000,-89162000,5.629,0.80651003,-0.33576,0.29943,SEK,XBRANE.ST,en-US,US,Equity,Free Realtime Quote,True,HIGH,False,1454486400000,-0.0013999939,0.2422 - 0.2542,Stockholm,15245625,0.117599994,0.9318541,0.1262 - 0.306,-0.062199995,-0.20326796,-5.8733225,-0.57096,0.2438,1756274400,1756274400,1756274400,1746687600,1746687600,False,0.05,0.02,0.19404,1.256442,0.010312006,0.044165038,0.048745498,0.24990706,False,15,0,REGULAR,[],1751530135,STO,finmb_130737517,Europe/Stockholm,CEST,7200000,se_market,False,Xbrane Biopharma AB,Xbrane Biopharma AB (publ),
